open access

Vol 12, No 4 (2016)
Congress abstract / Abstract
Published online: 2016-12-22
Get Citation

ESMO Congress 2016: Three of the most important studies in the field of breast cancer

Dorota Kwapisz
DOI: 10.5603/OCP.2016.0007
·
Oncol Clin Pract 2016;12(4):158-160.

open access

Vol 12, No 4 (2016)
CONGRESS REPORT
Published online: 2016-12-22

Abstract

The 2016 European Society for Medical Oncology (ESMO) annual congress highlighted the latest discoveries in different types of cancer research, including breast cancer. Immunotherapy and targeted therapies are the most rapidly evolving. This year’s meeting featured studies on targeted therapy (CDK4/6 inhibitor) plus endocrine therapy for advanced/metastatic breast cancer, a new approach in endocrine treatment, or possibility of using molecular/biological features in specific groups of patients to identify those for whom sentinel lymph node biopsy might be avoided. In this paper three selected studies dedicated to breast cancer patients, presented during the meeting, will be discussed.

Abstract

The 2016 European Society for Medical Oncology (ESMO) annual congress highlighted the latest discoveries in different types of cancer research, including breast cancer. Immunotherapy and targeted therapies are the most rapidly evolving. This year’s meeting featured studies on targeted therapy (CDK4/6 inhibitor) plus endocrine therapy for advanced/metastatic breast cancer, a new approach in endocrine treatment, or possibility of using molecular/biological features in specific groups of patients to identify those for whom sentinel lymph node biopsy might be avoided. In this paper three selected studies dedicated to breast cancer patients, presented during the meeting, will be discussed.

Get Citation

Keywords

ESMO, congress, breast cancer, CDK4/6 inhibitor, endocrine therapy

About this article
Title

ESMO Congress 2016: Three of the most important studies in the field of breast cancer

Journal

Oncology in Clinical Practice

Issue

Vol 12, No 4 (2016)

Article type

Congress abstract / Abstract

Pages

158-160

Published online

2016-12-22

DOI

10.5603/OCP.2016.0007

Bibliographic record

Oncol Clin Pract 2016;12(4):158-160.

Keywords

ESMO
congress
breast cancer
CDK4/6 inhibitor
endocrine therapy

Authors

Dorota Kwapisz

References (12)
  1. www. esmo.org..
  2. www.fda.gov..
  3. https://clinicaltrials.gov.
  4. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive. Advanced Breast Cancer . 2016; 1056.
  5. Hortobagyi GN, Stemmer SM, Burris HA et al. First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC). European Society for Medical Oncology (ESMO) Kopenhaga, 2016.
  6. Rader J, Russell MR, Hart LS, et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013; 19(22): 6173–6182.
  7. Kim S, Loo A, Chopra R, et al. LEE011: an orally bioavailable, selective small molecule inhibitor of CDK4/6–reactivating Rb in cancer. Mol Cancer Ther. 2013; 12(11 Suppl): Abstract PR02.
  8. INTERVIEW: Gabriel Hortobagyi MD, Professor of Medicine, University of Texas MD Anderson Cancer Center, Houston, USA. http://www. audiomedica.com/oncology/cyclin-dependent-kinase-inhibitionovercomes-endocrine-resistance-in-advanced-breast-cancer/.
  9. Ellis MJ, Bondarenko I, Trishkina E et al. FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer. European Society for Medical Oncology (ESMO) Congress; Copenhagen, Denmark; 2016. Abstract for LBA14_PR.
  10. Bregni G, Meneghini E, Galli G, et al. Breast cancer Ki67, tumor size and axillary nodes relationship: it's complicated. Annals of Oncology. 2016; 27(suppl_6).
  11. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000; 182(3): 311–322.
  12. Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983; 31(1): 13–20.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl